Benzoxazole kinase inhibitors and methods of use

1. An isolated compound of Formula II-A-1:

or a pharmaceutically acceptable salt thereof, wherein:

X 1 is N and X 2 is N;

R 1 is hydrogen, -L-C 1-10 alkyl, -L-C 3-8 cycloalkyl, -L-C 1-10 alkylheterocyclyl,

-L-heteroalkyl, or -L-heterocyclyl, each of which is unsubstituted or substituted by one or more independent R 3 substituents;

L is a bond, C═O, —C(═O)O—, —C(═O)N(R 31 )—, —S—, —S(O)—, —S(O) 2 —, —S(O) 2 N(R 31 )—, or —N(R 31 )—;

k is 1;

E 2 is H;

W 2 is —O—, —NR 7 —, —S(O) 0-2 —, —C(O)—, —C(O)N(R 7 )—, —N(R 7 )C(O)—, —N(R 7 )C(O)N(R 8 )—, —N(R 7 )S(O)—, —N(R 7 )S(O) 2 —, —C(O)O—, —CH(R 7 )N(C(O)OR 8 )—, —CH(R 7 )N(C(O)R 8 )—, —CH(R 7 )N(SO 2 R 8 )—, —CH(R 7 )N(R 8 )—, —CH(R 7 )C(O)N(R 8 )—, —CH(R 7 )N(R 8 )C(O)—, —CH(R 7 )N(R 8 )S(O)—, or —CH(R 7 )N(R 8 )S(O) 2 —;

R 3 is hydrogen, halogen, —OH, —R 31 , —CF 3 , —OCF 3 , —OR 31 , —NR 31 R 32 , —NR 34 R 35 , —C(O)R 31 , or —CO 2 R 31 ;

R 2 is hydrogen, halogen, —OH, —R 31 , —CF 3 , —OCF 3 , —OR 31 , —NR 31 R 32 , —NR 34 R 35 , —C(O)R 31 , —CO 2 R 31 , —C(═O)NR 31 R 32 , —C(═O)NR 34 R 35 , —NO 2 , —CN, —S(O) 0-2 R 31 , —SO 2 NR 31 R 32 , —SO 2 NR 34 R 35 , —NR 31 C(═O)R 32 , —NR 31 C(═O)OR 32 , —NR 31 C(═O)NR 32 R 33 , —NR 31 S(O) 0-2 R 32 , —C(═S)OR 31 , —C(═O)SR 31 , —NR 31 C(═NR 32 )NR 33 R 32 , —NR 31 C(═NR 32 )OR 33 , —NR 31 C(═NR 32 )SR 33 , —OC(═O)OR 33 , —OC(═O)NR 31 R 32 , —OC(═O)SR 31 , —SC(═O)OR 31 , —P(O)OR 31 OR 32 , —SC(═O)NR 31 R 32 , bicyclic aryl, substituted monocyclic aryl, hetaryl, C 1-10 alkyl, C 3-8 cycloalkyl, C 1-10 alkyl-C 3-8 cycloalkyl, C 3-8 cycloalkyl- C 1-10 alkyl, C 3-8 cycloalkyl- C 2-10 alkenyl, C 3-8 cycloalkyl- C 2-10 alkynyl, C 2-10 alkyl-monocyclic aryl, monocyclic aryl-C 2-10 alkyl, C 1-10 alkylbicycloaryl, bicycloaryl —C 1-10 alkyl, substituted C 1-10 alkylaryl, substituted aryl-C 1-10 alkyl, C 1-10 alkylhetaryl, C 1-10 alkylheterocyclyl, C 2-10 alkenyl, C 2-10 alkynyl, C 2-10 alkenylaryl, C 2-10 alkenylhetaryl, C 2-10 alkenylheteroalkyl, C 2-10 alkenylheterocyclyl, C 2-10 alkynylaryl, C 2-10 alkynylhetaryl, C 2-10 alkynylheteroalkyl, C 2-10 alkynylheterocylyl, C 2-10 alkenyl-C 3-8 cycloalkyl, C 2-10 alkynyl-C 3-8 cycloalkenyl, C 1-10 alkoxy C 1-10 alkyl, C 1-10 alkoxyC 2-10 alkenyl, C 1-10 alkoxyC 2-10 alkynyl, heterocyclyl, heterocyclyl C 1-10 alkyl, heterocyclylC 2-10 alkenyl, heterocyclyl-C 2-10 alkynyl, aryl-C 2-10 alkenyl, aryl-C 2-10 alkynyl, aryl-heterocyclyl, hetaryl- C 1-10 alkyl, hetaryl-C 2-10 alkenyl, hetaryl-C 2-10 alkynyl, hetaryl-C 3-8 cycloalkyl, hetaryl-heteroalkyl, or hetaryl-heterocyclyl, wherein each of said bicyclic aryl, monocyclic aryl, or heteroaryl moiety is unsubstituted or is substituted with one or more independent halo, —OH, —R 31 , —CF 3 , —OCF 3 , —OR 31 , —NR 31 R 32 , —NR 34 R 35 , —C(O)R 31 , —CO 2 R 31 , —C(═O)NR 31 R 32 , —C(═O)NR 34 R 35 , —NO 2 , —CN, —S(O) 0-2 R 31 , —SO 2 NR 31 R 32 , —SO 2 NR 34 R 35 , —NR 31 C(═O)R 32 , —NR 31 C(═O)OR 32 , —NR 31 C(═O)NR 32 R 33 , —NR 31 S(O) 0-2 R 32 , —C(═S)OR 31 , —C(═O)SR 31 , —NR 31 C(═NR 32 )NR 33 R 32 , —NR 31 C(═NR 32 )OR 33 , —NR 31 C(═NR 32 )SR 33 , —OC(═O)OR 33 , —OC(═O)NR 31 R 32 , —OC(═O)SR 31 , —SC(═O)OR 31 , —P(O)OR 31 OR 32 , or —SC(═O)NR 31 R 32 , and wherein each of said alkyl, cycloalkyl, heterocyclyl, or heteroalkyl moiety is unsubstituted or is substituted with one or more halo, —OH, —R 31 , —CF 3 , —OCF 3 , —OR 31 , —O-aryl, —NR 31 R 32 , —NR 34 R 35 , —C(O)R 31 , —CO 2 R 31 , —C(═O)NR 34 R 35 , or —C(═O)NR 31 R 32 ;

each of R 31 , R 32 , and R 33 is independently H or unsubstituted C 1-10 alkyl;

R 34 and R 35 in —NR 34 R 35 , —C(═O)NR 34 R 35 , or —SO 2 NR 34 R 35 , are taken together with the nitrogen atom to which they are attached to form a 3-10 membered saturated or unsaturated ring; wherein said ring is independently unsubstituted or is substituted by one or more —NR 31 R 32 hydroxyl, halogen, oxo, aryl, hetaryl, C 1-6 alkyl, or O-aryl, and wherein said 3-10 membered saturated or unsaturated ring independently contains 0, 1, or 2 more heteroatoms in addition to the nitrogen atom; and

each of R 7 and R 8 is independently hydrogen or C 1-10 alkyl.

2. The compound or pharmaceutically acceptable salt of the compound of claim 1 , wherein

R 1 is -L-C 1-10 alkyl, -L-C 3-8 cycloalkyl, -L-C 1-10 alkylheterocylyl, or -L-heterocyclyl, each of which is unsubstituted or is substituted by one or more independent R 3 substituents; and

R 3 is hydrogen, —OH, —OR 31 , —NR 31 R 32 , or —C(O)R 31 .

3. The compound or pharmaceutically acceptable salt of the compound of claim 1 , wherein —W 2 — is —NR′—, —N(R 7 )C(O)— or —N(R 7 )S(O) 2 —, and wherein R 7 is H.

4. The compound or pharmaceutically acceptable salt of the compound of claim 1 , wherein R 2 is H.

5. The compound or pharmaceutically acceptable salt of the compound of claim 1 , wherein:

R 1 is -L-C 1-10 alkyl or -L-C 3-8 cycloalkyl, each of which is unsubstituted or is substituted by one or more independent R 3 substituents, wherein R 3 is hydrogen, —OH, —OR 31 , or —C(O)R 31 .

6. The compound or pharmaceutically acceptable salt of the compound of claim 1 , wherein R 31 and R 32 are each H.

7. The compound or pharmaceutically acceptable salt of the compound of claim 1 , wherein the compound inhibits mammlian target of rapamycin (mTOR) at an IC 50 value of less than about 100 nM.

8. A composition comprising a compound or pharmaceutically acceptable salt of claim 1 , and a pharmaceutically acceptable carrier.

9. The composition of claim 8 , wherein

R 1 is -L-C 1-10 alkyl, -L-C 3-8 cycloalkyl, -L-C 1-10 alkylheterocylyl, or -L-heterocyclyl, each of which is unsubstituted or is substituted by one or more independent R 3 substituents; and

R 3 is hydrogen, —OH, —OR 31 , —NR 31 R 32 , or —C(O)R 31 .

10. The composition of claim 9 , wherein R 1 is -L-C 1-10 alkyl, -L-C 3-8 cycloalkyl, -L-C 1-10 alkylheterocylyl, or -L-heterocyclyl, each of which is unsubstituted.

11. The composition of claim 9 , wherein R 31 and R 32 are each H.

12. The composition of claim 9 , wherein —W 2 — is —NR 7 —, —N(R 7 )C(O)— or —N(R 7 )S(O) 2 —, and wherein R 7 is H.

13. The compound or pharmaceutically acceptable salt of the compound of claim 1 , wherein the compound is:

and wherein

R 1 is -L—C 1-10 alkyl, -L—C 3-8 cycloalkyl, -L-C 1-10 alkylheterocyclyl, or -L-heterocyclyl, each of which is unsubstituted or substituted by one or more independent R 3 substituents; and

R 3 is hydrogen, —OH, —OR 31 , —NR 31 R 32 , or —C(O)R 31 .

14. An isolated compound of Formula:

or a pharmaceutically acceptable salt thereof, wherein R 1 is —C 1-10 alkyl, —C 3-8 cycloalkyl, or —C 1-10 alkylheterocyclyl.

15. The compound or pharmaceutically acceptable salt of claim 14 , wherein R 1 is isopropyl.

16. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt of any one of claim 13 , 14 or 15 , and further comprising a pharmaceutical excipient.

17. The pharmaceutical composition of claim 16 , wherein the compound or pharmaceutically acceptable salt is in a therapeutically effective amount.

18. The pharmaceutical composition of claim 17 , wherein the compound or pharmaceutically acceptable salt is present in an amount between 0.0001-10 g.

19. The pharmaceutical composition of claim 18 , wherein the compound or pharmaceutically acceptable salt is present in an amount between 0.0005-9 g.

20. The pharmaceutical composition of claim 19 , wherein the compound or pharmaceutically acceptable salt is present in an amount between 0.01-6 g.

21. The pharmaceutical composition of claim 17 , wherein the compound or pharmaceutically acceptable salt is present in a concentration of greater than 10%.

22. The pharmaceutical composition of claim 17 , wherein the compound or pharmaceutically acceptable salt is present in a concentration of greater than 50%.

23. The pharmaceutical composition of claim 17 , wherein the compound or pharmaceutically acceptable salt is present in a concentration of greater than 80%.

24. The pharmaceutical composition of claim 16 , wherein the pharmaceutical excipient is chosen from the group consisting of detackifiers, anti-foaming agents, buffering agents, polymers, antioxidants, preservatives, chelating agents, viscomodulators, tonicifiers, flavorants, colorants, odorants, opacifiers, suspending agents, binders, fillers, plasticizers, lubricants, and mixtures thereof.

25. The pharmaceutical composition of claim 16 , wherein the pharmaceutical composition is a formulation for oral administration.

26. The pharmaceutical composition of claim 16 , wherein the pharmaceutical composition is a solid dosage form.

27. The pharmaceutical composition of claim 26 , wherein the solid dosage form is a powder, capsule or tablet.

28. The pharmaceutical composition of claim 26 , wherein the solid dosage form comprises a starch, sugar, micro-crystalline cellulose, diluent, granulating agent, lubricant, binder, or disintegrating agent.

29. The pharmaceutical composition of claim 16 , wherein the pharmaceutical composition is a liquid dosage form.

30. The compound or pharmaceutically acceptable salt of claim 1 , wherein the compound or pharmaceutically acceptable salt inhibits mTor at an IC 50 value of 10 nM or lower.

31. The compound or pharmaceutically acceptable salt of claim 1 , wherein the compound or pharmaceutically acceptable salt inhibits mTor at an IC 50 value of 5 nM or lower.